Neumora Therapeutics, Inc. Common Stock (NMRA) NASDAQ
2.00
-0.09(-4.31%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Neumora Therapeutics, Inc. Common Stock
Address
490 Arsenal Way
Watertown, DE 02472
United States of America (the)
Phone
857 760 0900
Website
Sector
Healthcare
Industry
Biotechnology
Employees
110
First IPO Date
September 15, 2023
Key Executives
| Name | Title | Pay | Year Born |
| Jason G. Duncan | Chief Legal & Administrative Officer | 315,000 | 1974 |
| Daljit Singh Aurora | Chief Operationg and development officer | 696,451 | 1968 |
| Joshua Pinto | President | 876,636 | 1984 |
| Nicholas Brandon | Chief Scientific Officer | 0 | 1975 |
| Helen Rubinstein | Head of Investor Relations | 0 | N/A |
| Michael Lee Milligan | Chief Financial Officer & Principal Accounting Officer | 0 | 1972 |
| Pablo Gersberg | Chief Information Officer | 0 | N/A |
| Amy Sullivan | Chief Human Resources Officer | 0 | N/A |
| Carol Suh | Co-Founder & Chief Strategy Officer | 0 | 1989 |
| Lori Houle | Chief Technical Operations & Quality Officer | 0 | 1967 |
Description
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
